Phase 2Active, not recruiting
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (ARC-10)
Official Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor
- Arcus Biosciences, Inc. (Industry)
- Enrolment
- 169 enrolled
- Conditions
- Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer; Lung Cancer
- Interventions
- Domvanalimab; Zimberelimab; Carboplatin; Paclitaxel; Pemetrexed; Pembrolizumab
- Ages
- adults, older adults
- Registry
- NCT04736173, CTIS2022-503071-28-00, EUCTR2020-003562-39
Full record on ClinicalTrials.gov
From the registry
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
Primary outcomes
- Progression-free Survival (PFS)
History
Primary completion expected
Last registry update
Started
Registered